CU24631B1 - Método para inactivar xenoantígenos en tejidos biológicos - Google Patents
Método para inactivar xenoantígenos en tejidos biológicosInfo
- Publication number
- CU24631B1 CU24631B1 CU2018000048A CU20180048A CU24631B1 CU 24631 B1 CU24631 B1 CU 24631B1 CU 2018000048 A CU2018000048 A CU 2018000048A CU 20180048 A CU20180048 A CU 20180048A CU 24631 B1 CU24631 B1 CU 24631B1
- Authority
- CU
- Cuba
- Prior art keywords
- xenoantigens
- inactivate
- biological tissues
- tissues
- hydroxytyrosol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Plant Substances (AREA)
- Prostheses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Biophysics (AREA)
- Physiology (AREA)
Abstract
<p>La presente invención se refiere a un método para inactivar xenoantígenos en tejidos biológicos aislados del cuerpo humano, que comprende: proporcionar una solución de ácido cafeico, de ácido tánico o de hidroxitirosol, para la inactivación del epítopo alfa-Gal de dichos tejidos; incubar las muestras y someter los tejidos tratados a tres lavados.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A006019A ITUB20156019A1 (it) | 2015-11-30 | 2015-11-30 | Metodo per l'inattivazione di xenoantigeni in tessuti biologici |
| PCT/EP2016/078898 WO2017093147A1 (en) | 2015-11-30 | 2016-11-25 | Method for inactivating xenoantigens in biological tissues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180048A7 CU20180048A7 (es) | 2018-11-06 |
| CU24631B1 true CU24631B1 (es) | 2022-12-12 |
Family
ID=55485194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000048A CU24631B1 (es) | 2015-11-30 | 2016-11-25 | Método para inactivar xenoantígenos en tejidos biológicos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20180353647A1 (es) |
| EP (1) | EP3383446B1 (es) |
| JP (1) | JP7169645B2 (es) |
| KR (1) | KR20180090816A (es) |
| CN (1) | CN108367098B (es) |
| AU (1) | AU2016363536B2 (es) |
| BR (1) | BR112018011021B1 (es) |
| CU (1) | CU24631B1 (es) |
| DK (1) | DK3383446T3 (es) |
| ES (1) | ES2881603T3 (es) |
| IL (1) | IL259591B (es) |
| IT (1) | ITUB20156019A1 (es) |
| MX (1) | MX385515B (es) |
| PL (1) | PL3383446T3 (es) |
| RS (1) | RS62100B1 (es) |
| RU (1) | RU2754197C2 (es) |
| WO (1) | WO2017093147A1 (es) |
| ZA (1) | ZA201803786B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600115523A1 (it) * | 2016-11-16 | 2018-05-16 | Biocompatibility Innovation Srl | Metodo per l'inattivazione ed il controllo di avvenuta inattivazione di xenoantigeni in alimenti di origine animale, particolarmente per latte e derivati, e in alimenti di origine vegetale, particolarmente per succedanei di latte a base di soia e/o riso |
| MX2021014295A (es) * | 2019-05-22 | 2022-01-06 | Biocompatibility Innovation Srl | Metodo para prevenir la formacion de depositos calcificados y para inactivar xenoantigenos en matrices biologicas. |
| AU2023436112A1 (en) | 2023-03-14 | 2025-10-09 | Biocompatibility Innovation S.r.l. | A method for imparting antimicrobial properties to a synthetic substrate |
| WO2025257595A1 (en) | 2024-06-12 | 2025-12-18 | Biocompatibility Innovation S.r.l. | Preserving solution |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520825A (ja) | 2000-01-25 | 2003-07-08 | ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ネブラスカ | 抗ドナー免疫へ抵抗する、移植前に順応された臓器 |
| US20040153145A1 (en) * | 2002-11-26 | 2004-08-05 | Clemson University | Fixation method for bioprostheses |
| ES2680569T3 (es) * | 2004-03-17 | 2018-09-10 | Revivicor Inc. | Productos de tejidos derivados de animales que carecen de cualquier expresión de alfa-1,3-galactosiltransferasa funcional |
| WO2007059439A1 (en) * | 2005-11-10 | 2007-05-24 | Hill's Pet Nutrition, Inc. | Compositions and methods for improving skin health and pelage quality |
| US20070282422A1 (en) * | 2006-05-10 | 2007-12-06 | Cook Incorporated | Medical devices and methods for local delivery of elastin-stabilizing compounds |
| CN101366979B (zh) * | 2008-09-03 | 2012-08-29 | 陕西瑞盛生物科技有限公司 | 一种组织补片及其制备方法 |
| FR2947456B1 (fr) * | 2009-07-06 | 2012-03-09 | Univ Bordeaux 1 | Procede d'inactivation d'au moins un agent pathogene dans un echantillon de plasma sanguin humain |
| IL210162A0 (en) * | 2010-12-21 | 2011-03-31 | Omrix Biopharmaceuticals | Viral inactivated platelet extract, use and preparation thereof |
| JP2014516695A (ja) | 2011-05-18 | 2014-07-17 | バトリックス・メディカル・インコーポレイテッド | 血管安定化用被覆バルーン |
| RU2495928C2 (ru) * | 2012-01-30 | 2013-10-20 | Сергей Юрьевич Лешков | Средство для стимуляции синтеза белков теплового шока hsp 70 в клетках человека и животных; косметическое средство для стимуляции репаративных процессов; косметическое средство для снижения побочных эффектов агрессивных косметологических процедур; биологически активная добавка; пищевой продукт; способ снижения побочных эффектов агрессивных косметологических процедур |
| ITPD20120029A1 (it) | 2012-02-09 | 2013-08-10 | Alessandro Gandaglia | Metodo per la rilevazione di uno xenoantigene in tessuti fissati usati come sostituti bioprotesici |
| US9283241B2 (en) * | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
| US9795573B2 (en) | 2013-09-24 | 2017-10-24 | Clemson University | Multi-step connective tissue stabilization method and stabilized tissue formed thereby |
| US11951078B2 (en) * | 2019-05-22 | 2024-04-09 | Biocompatibility Innovation S.r.l. | Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices |
-
2015
- 2015-11-30 IT ITUB2015A006019A patent/ITUB20156019A1/it unknown
-
2016
- 2016-11-25 EP EP16801773.9A patent/EP3383446B1/en active Active
- 2016-11-25 US US15/779,953 patent/US20180353647A1/en active Pending
- 2016-11-25 RU RU2018123621A patent/RU2754197C2/ru active
- 2016-11-25 CU CU2018000048A patent/CU24631B1/es unknown
- 2016-11-25 WO PCT/EP2016/078898 patent/WO2017093147A1/en not_active Ceased
- 2016-11-25 MX MX2018006577A patent/MX385515B/es unknown
- 2016-11-25 ES ES16801773T patent/ES2881603T3/es active Active
- 2016-11-25 BR BR112018011021-3A patent/BR112018011021B1/pt active IP Right Grant
- 2016-11-25 RS RS20210866A patent/RS62100B1/sr unknown
- 2016-11-25 PL PL16801773T patent/PL3383446T3/pl unknown
- 2016-11-25 JP JP2018546756A patent/JP7169645B2/ja active Active
- 2016-11-25 KR KR1020187016622A patent/KR20180090816A/ko not_active Ceased
- 2016-11-25 CN CN201680069993.5A patent/CN108367098B/zh active Active
- 2016-11-25 AU AU2016363536A patent/AU2016363536B2/en active Active
- 2016-11-25 DK DK16801773.9T patent/DK3383446T3/da active
-
2018
- 2018-05-24 IL IL259591A patent/IL259591B/en unknown
- 2018-06-07 ZA ZA2018/03786A patent/ZA201803786B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108367098B (zh) | 2021-06-11 |
| RS62100B1 (sr) | 2021-08-31 |
| ITUB20156019A1 (it) | 2017-05-30 |
| US20180353647A1 (en) | 2018-12-13 |
| CN108367098A (zh) | 2018-08-03 |
| MX385515B (es) | 2025-03-18 |
| CA3006234A1 (en) | 2017-06-08 |
| JP7169645B2 (ja) | 2022-11-11 |
| EP3383446B1 (en) | 2021-04-28 |
| EP3383446A1 (en) | 2018-10-10 |
| CU20180048A7 (es) | 2018-11-06 |
| RU2018123621A3 (es) | 2020-04-10 |
| AU2016363536B2 (en) | 2021-04-01 |
| PL3383446T3 (pl) | 2021-11-02 |
| RU2018123621A (ru) | 2020-01-09 |
| IL259591A (en) | 2018-07-31 |
| BR112018011021B1 (pt) | 2021-12-07 |
| DK3383446T3 (da) | 2021-07-26 |
| BR112018011021A2 (pt) | 2018-11-21 |
| KR20180090816A (ko) | 2018-08-13 |
| ZA201803786B (en) | 2019-02-27 |
| WO2017093147A1 (en) | 2017-06-08 |
| AU2016363536A1 (en) | 2018-06-28 |
| JP2019503821A (ja) | 2019-02-14 |
| ES2881603T3 (es) | 2021-11-30 |
| MX2018006577A (es) | 2018-09-05 |
| RU2754197C2 (ru) | 2021-08-30 |
| IL259591B (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| DOP2017000186A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| EP3468356A4 (en) | GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| BR112017022768A2 (pt) | desinfecção de tecido com ondas de choque de pressão acústica | |
| CO6640274A2 (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| UY36458A (es) | Anticuerpos humanos para hemaglutinina influenza. | |
| UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
| CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
| CR20160269A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes | |
| MX2016012938A (es) | Composiciones estables de yodo no en complejo y metodos de uso. | |
| IL257818A (en) | Compositions and methods for multipurpose disinfection and sterilization solutions | |
| CL2014000432A1 (es) | Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. | |
| GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| MX2017008277A (es) | Solucion oftalmica acuosa. | |
| BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
| CU24631B1 (es) | Método para inactivar xenoantígenos en tejidos biológicos | |
| BR112018009004A2 (pt) | conjugados anti-cd3-folato e seus usos | |
| BR112016028895A2 (pt) | composições biofotônicas termofixas e usos destas | |
| MX2017008823A (es) | Metodos para aislamiento de plaquetas. | |
| AR104598A1 (es) | Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t | |
| MX2015016057A (es) | Solucion estabilizada de acido hipocloroso y uso de la misma. |